Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-09-07
Schrödinger, Inc.
Schrödinger sells molecular discovery software and AI-enabled workflows to biopharma and other research customers while retaining upside from partnered and proprietary drug programs.
ai biotech cloud healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From modeling tool to discovery control layer
This is a bet that AI makes drug discovery workflows more valuable, not less. The equity works if hosted delivery and Bunsen move spend toward recurring program-level control; it disappoints if customers buy the science but keep the orchestration layer in-house.

Analysis

Thesis
The five-year upside is a business-model upgrade: if hosted delivery, LiveDesign embedding, and Bunsen shift Schrödinger from specialist modeling vendor to governed discovery workflow owner, rising AI-era discovery throughput can convert into cleaner recurring revenue and selective milestone upside without needing a single binary drug win.
Last Economy Alignment
Cheaper cognition should increase discovery workflow demand, and Schrödinger has real control points in workflow and scientific trust. But it does not own the compute or the data rail, so open tools and internal pharma stacks can still compress value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.8x (from 5 most recent analyses)
Reasoning
The core bet is that hosted delivery makes reported revenue more durable and Bunsen expands Schrödinger from expert users into broader team workflows. If that happens, the market can value the company more like a sticky discovery software control layer and less like a lumpy mixed software-biotech story. The upside needs repeatable expansion across large accounts, not a single drug jackpot.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is economic capture, not scientific relevance. Schrödinger likely stays useful in AI-era discovery, but the equity case weakens if hosted delivery mainly changes accounting, if Bunsen lifts usage without lifting paid workflow control, or if a handful of large accounts and collaborators keep revenue too uneven for a durable rerating.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.40
They help drug teams do more thinking and testing with the same scientists, and they already control a meaningful part of the shared workflow where decisions get tracked and verified. The risk is that cheaper open tools or internal pharma systems capture the control layer while Schrödinger supplies useful science underneath.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$21.43
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case